The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Viva Biotech Holdings's Revenue for the
six
months ended in Dec. 2025 was €108.8 Mil. Viva Biotech Holdings's average Accounts Receivable for the
six
months ended in Dec. 2025 was €41.5 Mil.
Hence, Viva Biotech Holdings's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.63.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Viva Biotech Holdings Receivables Turnover Related Terms
Viva Biotech Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Receivables Turnover of 2.63 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Viva Biotech Holdings and its competitors. According to the industry distribution chart, Viva Biotech Holdings ranks #462 out of 841 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Viva Biotech Holdings' Receivables Turnover too high?
Viva Biotech Holdings' current Receivables Turnover is 2.63. The Biotechnology industry median Receivables Turnover is 5.29. Viva Biotech Holdings' value of 2.63 is 50.3% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #462 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #462 out of 841 companies for Receivables Turnover. This places Viva Biotech Holdings in the lower half of its industry. The industry median Receivables Turnover is 5.29. Viva Biotech Holdings' value of 2.63 is 50.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Receivables Turnover of 2.63 is 50.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Receivables Turnover is 2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 66.3% above its estimated fair value. The current Receivables Turnover is 2.63 and 50.3% below the Biotechnology industry median of 5.29. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Receivables Turnover is 2.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.13 is trading 66.3% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Receivables Turnover: 2.63
GF Value™: €0.08 vs. price of €0.13 (66.3% above fair value)
Industry Position: 50.3% below the Biotechnology median (#462 of 841)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
